Hormone Journal

Genitourinary syndrome of menopause

Also known as: GSM, vaginal dryness, vulvovaginal atrophy

Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22

Genitourinary syndrome of menopause (GSM) is a progressive, estrogen-deficiency condition affecting the vagina, vulva, and urinary tract that impacts up to 84% of postmenopausal women.

What it is

Genitourinary syndrome of menopause (GSM) is a progressive condition caused by declining estrogen levels during and after menopause that affects the vaginal, vulvar, urethral, and bladder tissues — producing dryness, painful sex, and urinary symptoms in an estimated 27% to 84% of postmenopausal women. The term GSM was introduced in 2014 by the International Society for the Study of Women's Sexual Health and The Menopause Society (formerly NAMS) to replace the older labels "vaginal atrophy" and "atrophic vaginitis," which failed to capture the full scope of genitourinary involvement. Unlike vasomotor symptoms such as hot flashes, which typically ease over time, GSM is progressive: without treatment, symptoms worsen as the low-estrogen state of postmenopause persists. Despite its prevalence, GSM remains significantly underreported — many women accept the symptoms as an unavoidable part of aging, and many clinicians do not routinely screen for them. Effective, well-tolerated treatments exist and can substantially improve quality of life and sexual health.

In Canada, postmenopausal women can discuss GSM with their family physician, gynaecologist, or through virtual menopause care platforms such as Felix, Cleo, Maple, Phoenix, or others. The Society of Obstetricians and Gynaecologists of Canada (SOGC) addresses GSM within its menopause management guidelines.

Causes and mechanism

The primary driver of GSM is the sharp decline in estradiol (the dominant form of estrogen) that occurs during the menopause transition. The vulva, vagina, urethra, and bladder all carry estrogen receptors and are highly sensitive to this loss. Several interconnected changes follow:

  • Epithelial thinning: Estrogen normally maintains the thickness and folded texture (rugosity) of vaginal walls. Without it, the epithelium thins and becomes fragile and prone to microtrauma.
  • Loss of lubrication: Estrogen-sensitive cells that produce natural vaginal secretions decline in number and activity, causing dryness.
  • pH shift: Estrogen supports the Lactobacillus-dominant vaginal microbiome that keeps pH acidic (below 4.5). As estrogen falls, pH rises above 5, increasing susceptibility to infection and irritation.
  • Urethral and bladder changes: Atrophic changes in urethral and bladder tissue contribute to urgency, frequency, and recurrent urinary tract infections (UTIs).

Certain situations accelerate GSM onset or severity:

Accelerating factorMechanism
Surgical menopause (bilateral oophorectomy)Abrupt, complete estrogen loss
Aromatase inhibitors / tamoxifenPharmacological estrogen suppression
Prolonged breastfeedingProlactin-mediated estrogen suppression
Sexual inactivityReduced pelvic blood flow, hastening tissue changes
Chemotherapy or pelvic radiationDirect tissue damage plus estrogen disruption

Symptoms and diagnosis

GSM produces a spectrum of vulvovaginal, urinary, and sexual symptoms that tend to intensify over time without treatment.

Vulvovaginal: vaginal dryness (often the most prominent complaint), irritation, itching or burning, a sensation of tightness or narrowing, painful intercourse (dyspareunia), postcoital spotting from fragile tissue, and recurrent vaginal infections.

Urinary: urgency, increased frequency, recurrent UTIs, mild stress or urge incontinence, and burning on urination.

Sexual: reduced arousal and lubrication, difficulty reaching orgasm, and avoidance of sexual activity due to anticipated pain.

Diagnosis is primarily clinical:

  1. Symptom history — genital, urinary, and sexual symptoms in the context of menopausal status or estrogen-lowering treatments.
  2. Physical examination — vaginal mucosa appears pale, thin, and smooth; pH testing typically shows values above 5.
  3. Hormonal panel — serum FSH and estradiol if menopausal status needs confirmation. In Canada, these tests are available through LifeLabs, Dynacare, or provincial laboratory networks on physician requisition.
  4. Urine culture — to investigate recurrent UTIs.

Treatment options

GSM is highly treatable. Most women experience meaningful improvement with appropriate therapy, and earlier treatment generally produces better tissue response.

Local (first-line) hormonal therapies — minimal systemic absorption, generally safe for most women including many with contraindications to systemic hormone therapy:

  • Vaginal estrogen (cream, tablet/pessary, or ring): the most evidence-supported local treatment. Restores epithelial thickness, lubrication, and vaginal pH. Requires ongoing use to maintain benefit.
  • Vaginal DHEA / prasterone (Intrarosa): a locally applied suppository converted to both estrogen and testosterone within vaginal tissue. Effective for vaginal dryness and sexual symptoms.
  • Ospemifene (Osphena): an oral selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue. An option for women who prefer not to use vaginal preparations.

Systemic hormone therapy (HT): appropriate for women who also have vasomotor symptoms or who prefer a systemic approach. Some women on systemic HT still benefit from adding local vaginal therapy for optimal genitourinary effect.

Non-hormonal options:

  • Vaginal moisturizers (e.g., Replens, Hyalo-Gyn): used several times per week to maintain baseline vaginal hydration — not only during sexual activity.
  • Vaginal lubricants: used at the time of sexual activity to reduce friction; they do not address underlying tissue changes.
  • Regular sexual stimulation: maintains pelvic blood flow and supports vaginal tissue health.
  • Pelvic floor physiotherapy: can address tightness, incontinence, and dyspareunia; widely available across Canadian provinces.

When to see a clinician in Canada

Seek care if you are experiencing vaginal dryness, discomfort, pain during sex, recurrent UTIs, or urinary urgency in the context of perimenopause, postmenopause, or after treatments that suppress estrogen (such as aromatase inhibitors used in breast cancer management). These symptoms are common, treatable, and worth raising — even if your clinician has not asked. The earlier treatment begins, the better the tissue response tends to be.

In Canada, GSM can be assessed and managed by a family physician, gynaecologist, or nurse practitioner. Virtual care platforms (Felix, Cleo, Maple, Phoenix, and others) offer menopause-focused consultations for patients in provinces where telehealth prescribing is available. Coverage for vaginal estrogen and prasterone varies by provincial drug benefit plan; check your provincial formulary or ask your pharmacist.

Limitations and open questions

Research is still emerging on several aspects of GSM. The long-term safety of low-dose vaginal estrogen in women with hormone-receptor-positive breast cancer — particularly those on aromatase inhibitors — has not been definitively established; current guidance recommends individualized risk-benefit discussion with an oncologist. The optimal duration of treatment and whether early intervention meaningfully slows tissue progression compared with later treatment have not been settled in large randomized trials. Evidence on newer energy-based devices (fractional CO₂ laser, radiofrequency) for GSM is promising but inconsistent, and Health Canada has not issued formal guidance on their use for this indication. The role of androgens (testosterone) in GSM management beyond prasterone also requires further study. Patient-reported outcome measures for GSM are not yet standardized across Canadian clinical settings, which can make systematic screening inconsistent.

FAQs

Is vaginal estrogen safe to use after breast cancer?

This question requires an individualized conversation with both an oncologist and a gynaecologist. Current evidence suggests that low-dose vaginal estrogen produces very low systemic absorption — serum estradiol levels typically remain within the postmenopausal range — and major guidelines consider it potentially acceptable for many breast cancer survivors, particularly those not on aromatase inhibitors. For women taking aromatase inhibitors, non-hormonal moisturizers, vaginal prasterone (Intrarosa), or oral ospemifene (Osphena) are often recommended as alternatives, though the evidence base for these options in this population is still growing. No single answer applies to everyone; the decision depends on cancer type, stage, current treatment, and individual risk tolerance.

Do lubricants actually treat GSM, or just mask the symptoms?

Lubricants provide temporary relief during sexual activity by reducing friction, but they do not reverse the underlying tissue changes of GSM and do not prevent further atrophy. Vaginal moisturizers used regularly — typically 3 or more times per week — are more effective for managing day-to-day dryness and discomfort. For lasting improvement in vaginal tissue thickness, elasticity, and pH, treatment with local estrogen or prasterone is needed; studies show measurable histological changes in vaginal epithelium within 12 weeks of consistent use. Lubricants and moisturizers remain useful complements to hormonal therapy, especially during the initial weeks before full tissue response occurs.

Can GSM be reversed, or is it permanent?

GSM can be substantially reversed with appropriate treatment, though it is not cured in the sense that treatment must continue to maintain benefit. With consistent use of local vaginal estrogen, the vaginal epithelium can regain thickness and elasticity, natural lubrication improves, and vaginal pH returns toward a more protective acidic range — typically below 5. Clinical trials show significant symptom improvement in the majority of women within 8 to 12 weeks of starting local therapy. Because GSM is driven by the persistent low-estrogen state of postmenopause, stopping treatment leads to recurrence of symptoms over time.

Does GSM always cause painful sex, or can it show up differently?

GSM encompasses a spectrum of presentations, and painful intercourse (dyspareunia) is not universal. Some women experience primarily urinary symptoms — urgency, frequency, or recurrent UTIs — with minimal vaginal discomfort. Others have significant dryness and irritation but remain sexually inactive and so do not notice dyspareunia. What is consistent across presentations is that symptoms tend to worsen progressively over time without treatment, regardless of which symptoms are most prominent at first. The VIVA (Vaginal Health: Insights, Views and Attitudes) survey found that fewer than 25% of affected women had discussed their symptoms with a healthcare provider, suggesting many are managing silently across the full symptom spectrum.

Is treatment for GSM covered by provincial drug plans in Canada?

Coverage varies by province and by specific product. In several provinces, low-dose vaginal estrogen creams and rings are listed on provincial formularies and may be covered for eligible patients, often with a prescription and sometimes with special authorization. Prasterone (Intrarosa) and ospemifene (Osphena) are newer agents and coverage is more limited and inconsistent across provincial plans as of 2024. Patients should check their specific provincial drug benefit formulary — such as Ontario's ODB, BC PharmaCare, or Alberta's NIHB — or ask their pharmacist to confirm coverage and any prior-authorization requirements before starting treatment.

Sources

All glossary termsUpdated 2026-05-22